Cargando…
血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析
BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the survival of advanced lung adenocarcinoma patients harboring EGFR mutation. Limited to the standards of tumor tissue samples and detection methods, still some people can't...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973368/ https://www.ncbi.nlm.nih.gov/pubmed/28935011 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.09.01 |
_version_ | 1783326611702022144 |
---|---|
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the survival of advanced lung adenocarcinoma patients harboring EGFR mutation. Limited to the standards of tumor tissue samples and detection methods, still some people can't receive target therapy following genetic guidance. This study was to explore the relevance between serum tumor markers and treatment of EGFR-TKIs. METHODS: We retrospectively collected the clinical information of advanced lung adenocarcinoma patients harboring EGFR mutation, who received EGFR-TKIs as first-line therapy from June 2009 to June 2014 in Peking University Cancer Hospital, analyzed the relationship between serum tumor markers and efficacy of EGFR-TKIs. RESULTS: The objective response rate (ORR) was 52.8% and the disease control rate (DCR) was 89.3%. The results showed that, patients with high CEA level before treatment responded better to TKIs (ORR 61.3% vs 35.9%, DCR 95.2% vs 74.4%, P < 0.001). Similar phenomena was found in patients with CEA decreased 1 month later (61.5% vs 25%, P=0.002). Progression-free survival (PFS) significantly prolonged in patients with elevated baseline CEA (mPFS 9.8 mo vs 5.9 mo, P=0.027). To the opposite, PFS was significantly shorter in patients with elevated baseline CYFRA21-1 and CA125 (mPFS 9.0 mo vs 11.4 mo, P=0.029; 9.0 mo vs 11.5 mo, P=0.023, respectively). Multivariate analysis showed that Eastern Cooperative Oncology Group (ECOG) score of 0-1, normal baseline CYFRA21-1 and CEA decline predicted longer PFS. The overall survival (OS) was highly associated with elevated CYFRA21-1 and CA125 (median OS 25.1 mo vs 52.5 mo, P=0.003; 22.7 mo vs 55.0 mo, P < 0.001, respectively), while independent of CEA. CONCLUSION: High level of baseline CEA and decline 1 month after treatment could predict the efficacy of EGFR-TKIs in patients with advanced lung adenocarcinoma. While high levels of baseline CYFRA21-1 and CA125 indicated shortened survival. |
format | Online Article Text |
id | pubmed-5973368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-59733682018-07-06 血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the survival of advanced lung adenocarcinoma patients harboring EGFR mutation. Limited to the standards of tumor tissue samples and detection methods, still some people can't receive target therapy following genetic guidance. This study was to explore the relevance between serum tumor markers and treatment of EGFR-TKIs. METHODS: We retrospectively collected the clinical information of advanced lung adenocarcinoma patients harboring EGFR mutation, who received EGFR-TKIs as first-line therapy from June 2009 to June 2014 in Peking University Cancer Hospital, analyzed the relationship between serum tumor markers and efficacy of EGFR-TKIs. RESULTS: The objective response rate (ORR) was 52.8% and the disease control rate (DCR) was 89.3%. The results showed that, patients with high CEA level before treatment responded better to TKIs (ORR 61.3% vs 35.9%, DCR 95.2% vs 74.4%, P < 0.001). Similar phenomena was found in patients with CEA decreased 1 month later (61.5% vs 25%, P=0.002). Progression-free survival (PFS) significantly prolonged in patients with elevated baseline CEA (mPFS 9.8 mo vs 5.9 mo, P=0.027). To the opposite, PFS was significantly shorter in patients with elevated baseline CYFRA21-1 and CA125 (mPFS 9.0 mo vs 11.4 mo, P=0.029; 9.0 mo vs 11.5 mo, P=0.023, respectively). Multivariate analysis showed that Eastern Cooperative Oncology Group (ECOG) score of 0-1, normal baseline CYFRA21-1 and CEA decline predicted longer PFS. The overall survival (OS) was highly associated with elevated CYFRA21-1 and CA125 (median OS 25.1 mo vs 52.5 mo, P=0.003; 22.7 mo vs 55.0 mo, P < 0.001, respectively), while independent of CEA. CONCLUSION: High level of baseline CEA and decline 1 month after treatment could predict the efficacy of EGFR-TKIs in patients with advanced lung adenocarcinoma. While high levels of baseline CYFRA21-1 and CA125 indicated shortened survival. 中国肺癌杂志编辑部 2017-09-20 /pmc/articles/PMC5973368/ /pubmed/28935011 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.09.01 Text en 版权所有©《中国肺癌杂志》编辑部2017 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 临床研究 血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析 |
title | 血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析 |
title_full | 血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析 |
title_fullStr | 血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析 |
title_full_unstemmed | 血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析 |
title_short | 血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析 |
title_sort | 血清肿瘤标志物与一线egfr-tkis治疗晚期egfr突变型肺腺癌患者疗效相关性分析 |
topic | 临床研究 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973368/ https://www.ncbi.nlm.nih.gov/pubmed/28935011 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.09.01 |
work_keys_str_mv | AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī |